Iguratimod: a valuable remedy from the Asia Pacific region for ameliorating autoimmune diseases and protecting bone physiology

Abstract

Autoimmune diseases are affected by complex pathophysiology involving several cell types, cytokines, antibodies, and mimicking factors. Different drugs are used to ameliorate these autoimmune reactions, including nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, antiantibodies, and small molecular drugs (DMARDs), and they are clinically in vogue for diseases such as rheumatoid arthritis (RA). Nevertheless, low cost-effectiveness, reduced efficacy, adverse effects, and patient nonresponse are unappealing factors driving the development of new drugs such as iguratimod. Iguratimod is primarily used to ameliorate RA in Japanese and Chinese clinics. However, its efficacy against other autoimmune ailments is also under intense investigation, and the number of investigations is becoming increasingly larger with each passing day. The articular structure comprises synovium, ligaments, and bone. The latter is more complex than the others since it regulates blood cells and autoimmunity in addition to providing skeletal support to the body. Therefore, its protection is also of prime importance in RA and other autoimmune diseases. Herein, we have highlighted the role of iguratimod in autoimmune diseases and bone protection. We suggest that iguratimod’s unique mode of action compared with that of other DMARDs and its good patient response makes it a suitable antirheumatic and bone-protecting drug.

References

[1] Sinha AA et al. Autoimmune diseases: the failure of self tolerance. Science, 1990, 248:1380-1388

[2] Lerner A et al. The world incidence and prevalence of autoimmune diseases is increasing. Int. J. Celiac Dis., 2015, 3:151-155

[3] Criswell LA et al. Analysis of families in the multiple autoimmune disease genetics consortium (MADGC) collection: the PTPN22 620W allele associates with multiple autoimmune phenotypes. Am. J. Hum. Genet., 2005, 76:561-571

[4] Dominguez-Villar M, Hafler DA. Regulatory T cells in autoimmune disease. Nat. Immunol., 2018, 19:665-673

[5] Zhao C et al. Bio-imaging and photodynamic therapy with tetra sulphonatophenyl porphyrin (TSPP)-TiO2 nanowhiskers: new approaches in rheumatoid arthritis theranostics. Sci. Rep., 2015, 5

[6] Firestein GS. Evolving concepts of rheumatoid arthritis. Nature, 2003, 423:356-361

[7] Coussens LM, Werb Z. Inflammation and cancer. Nature, 2002, 420:860-867

[8] Meyer LH et al. The role of mesenchymal cells in the pathophysiology of inflammatory arthritis. Best. Pract. Res. Clin. Rheumatol., 2006, 20:969-981

[9] Buckley CD et al. Defining a role for fibroblasts in the persistence of chronic inflammatory joint disease. Ann. Rheum. Dis., 2004, 63:ii92-ii95

[10] Lau CS et al. APLAR rheumatoid arthritis treatment recommendations. Int. J. Rheum. Dis., 2015, 18:685-713

[11] Tanaka K et al. Pharmacological studies of the new antiinflammatory agent 3-formylamino-7-methylsulfonylamino-6-phenoxy-4’-1-benzopyran-4-o ne. 2nd communication: effect on the arachidonic acid cascades. Arzneimittelforschung, 1992, 42:945-950

[12] Tanaka K et al. Pharmacological studies of the new antiinflammatory agent 3-formylamino-7-methylsulfonylamino-6-phenoxy-4H-1-benzopyran-4-o ne. 1st communication: antiinflammatory, analgesic and other related properties. Arzneimittelforschung, 1992, 42:935-944

[13] Tanaka K et al. Pharmacological studies on 3-formylamino-7-methylsulfonylamino-6-phenoxy-4H-1-benzopyran-4-one (T-614), a novel antiinflammatory agent. 3rd communication: the involvement of bradykinin in its analgesic actions. J. Pharm., 1992, 15:641-647

[14] Tanaka K et al. Pharmacological studies on 3-formylamino-7-methylsulfonylamino-6-phenoxy-4H-1-benzopyran-4-one (T-614), a novel antiinflammatory agent. 4th communication: inhibitory effect on the production of interleukin-1 and interleukin-6. J. Pharm., 1992, 15:649-655

[15] Mucke HA. Iguratimod: a new disease-modifying antirheumatic drug. Drugs, 2012, 577:today48

[16] Tanaka K. Iguratimod (T-614): a novel disease modifying anti-rheumatic drug. Rheumatol. Rep., 2009, 1:4

[17] Inaba T et al. Synthesis and antiinflammatory activity of 7-methanesulfonylamino-6-phenoxychromones. antiarthritic effect of the 3-formylamino compound (T-614) in chronic inflammatory cisease models. Chem. Pharm. Bull., 2000, 48:131-139

[18] Swingle KF et al. 4-nitro-2-phenoxymethanesulfonanilide (R-805): a chemically novel anti-inflammatory agent. Arch. Int. Pharmacodyn. Ther., 1976, 221:132-139

[19] Tanaka K et al. T-614, a novel antirheumatic drug, inhibits both the activity and induction of cyclooxygenase-2 (COX-2) in cultured fibroblasts. Jpn. J. Pharmacol., 1995, 67:305-314

[20] Xiao F et al. A randomized phase I study to evaluate the safety, tolerability, pharmacokinetics and food-effect of Iguratimod in healthy adult volunteers. Eur. J. Clin. Pharmacol., 2018, 74:69-77

[21] Kohno M et al. Inhibitory effect of T-614 on tumor necrosis factor-alpha induced cytokine production and nuclear factor-kappaB activation in cultured human synovial cells. J. Rheumatol., 2001, 28:2591-2596

[22] Luo Q et al. A novel disease-modifying antirheumatic drug, iguratimod, ameliorates murine arthritis by blocking IL-17 signaling, distinct from methotrexate and leflunomide. J. Immunol., 2013, 191:4969-4978

[23] Jiang Y et al. Inhibitory effect of iguratimod on TNF alpha production and NF-kappaB activity in LPS-stimulated rat alveolar macrophage cell line. Yao Xue Xue Bao, 2006, 41:401-405

[24] Moran EM et al. Human rheumatoid arthritis tissue production of IL-17A drives matrix and cartilage degradation: synergy with tumour necrosis factor-alpha, Oncostatin M and response to biologic therapies. Arthritis Res. Ther., 2009, 11:R113

[25] Xu Y et al. Regulatory effect of iguratimod on the balance of th subsets and inhibition of inflammatory cytokines in patients with rheumatoid arthritis. Mediat. Inflamm., 2015, 2015:356040

[26] Aikawa Y et al. An anti-rheumatic agent T-614 inhibits NF-κB activation in LPS-and TNF-α-stimulated THP-1 cells without interfering with IκBα degradation. Inflamm. Res., 2002, 51:188-194

[27] Kawakami A et al. Inhibitory effect of a new anti-rheumatic drug T-614 on costimulatory molecule expression, cytokine production, and antigen presentation by synovial cells. J. Lab. Clin. Med., 1999, 133:566-574

[28] Yamamoto M et al. Effect of a disease-modifying antirheumatic drug iguratimod (T-614) on inflammatory cytokine production. Jpn. J. Pharmacol. Ther., 2007, 35:551-559

[29] Hara M et al. Efficacy and safety of iguratimod compared with placebo and salazosulfapyridine in active rheumatoid arthritis: a controlled, multicenter, double-blind, parallel-group study. Mod. Rheumatol., 2007, 17:1-9

[30] Du F et al. T-614, a novel immunomodulator, attenuates joint inflammation and articular damage in collagen-induced arthritis. Arthritis Res. Ther., 2008, 10:R136

[31] Smolen JS et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann. Rheum. Dis., 2014, 73:492-509

[32] Hsu L, Armstrong AW. JAK inhibitors: treatment efficacy and safety profile in patients with psoriasis. J. Immunol. Res., 2014, 2014:283617

[33] Sandberg ME et al. Overweight decreases the chance of achieving good response and low disease activity in early rheumatoid arthritis. Ann. Rheum. Dis., 2014, 73:2029-2033

[34] Kremer JM. Methotrexate and leflunomide: biochemical basis for combination therapy in the treatment of rheumatoid arthritis. Semin. arthritis Rheum., 1999, 29:14-26

[35] Jonsson B et al. The burden of rheumatoid arthritis and access to treatment: uptake of new therapies. Eur. J. Health Econ., 2008, 8:S61-S86

[36] Xu H et al. Effects of combination of Iguratimod and NSAID on clinical indices and inflammatory markers in patients with rheumatoid arthritis. Int. J. Clin. Exp. Med., 2016, 9:16511-16516

[37] Ishiguro N et al. Concomitant iguratimod therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate: a randomized, double-blind, placebo-controlled trial. Mod. Rheumatol., 2013, 23:430-439

[38] Tian H, Cronstein BN. Understanding the mechanisms of action of methotrexate: implications for the treatment of rheumatoid arthritis. Bull. NYU Hosp. Jt. Dis., 2007, 65:168-173

[39] Cutolo M et al. Anti-inflammatory mechanisms of methotrexate in rheumatoid arthritis. Ann. Rheum. Dis., 2001, 60:729-735

[40] Breedveld FC, Dayer JM. Leflunomide: mode of action in the treatment of rheumatoid arthritis. Ann. Rheum. Dis., 2000, 59:841-849

[41] Tokunaga K et al. THU0198 Comparison of efficacy between combination therapy with iguratimod and sulfasalazine with methotrexate in japanese patients with rheumatoid arthritis: propensity score analysis. Ann. Rheum. Dis., 2017, 76:278-278

[42] Ebina K et al. The add-on effectiveness and safety of iguratimod in patients with rheumatoid arthritis who showed an inadequate response to tocilizumab. Mod. Rheumatol., 2018, 29:1-8

[43] Rehman FU et al. Influence of photoactivated tetra sulphonatophenyl porphyrin and TiO₂ nanowhiskers on rheumatoid arthritis infected bone marrow stem cells proliferation in vitro and oxidative stress biomarkers in vivo. RSC Adv., 2015, 5:107285-107292

[44] Rehman FU et al. Synergy and translation of allogenic bone marrow stem cells after photodynamic treatment of rheumatoid arthritis with tetra sulfonatophenyl porphyrin and TiO2 nanowhiskers. Nano Res., 2016, 9:3305-3321

[45] Li J et al. Efficacy and safety of iguratimod for the treatment of rheumatoid arthritis. Clin. Dev. Immunol., 2013, 2013:310628

[46] Diarra D et al. Dickkopf-1 is a master regulator of joint remodeling. Nat. Med., 2007, 13:156

[47] Fardellone P et al. Bone remodelling markers in rheumatoid arthritis. Mediat. Inflamm., 2014, 2014:484280

[48] Schett G, Gravallese E. Bone erosion in rheumatoid arthritis: mechanisms, diagnosis and treatment. Nat. Rev. Rheumatol., 2012, 8:656-664

[49] van Tuyl LH et al. Baseline RANKL:OPG ratio and markers of bone and cartilage degradation predict annual radiological progression over 11 years in rheumatoid arthritis. Ann. Rheum. Dis., 2010, 69:1623-1628

[50] Weilbaecher KN et al. Cancer to bone: a fatal attraction. Nat. Rev. Cancer, 2011, 11:411-425

[51] Wang X et al. Effects of iguratimod on the levels of circulating regulators of bone remodeling and bone remodeling markers in patients with rheumatoid arthritis. Clin. Rheumatol., 2017, 36:1369-1377

[52] Wang XT et al. Effect of iguratimod and methotrexate on RANKL and OPG expression in serum and IL-1beta-induced fibroblast-like synoviocytes from patients with rheumatoid arthritis. Cell. Mol. Biol. (Noisy-le.-Gd.), 2016, 62:44-50

[53] Gravallese EM. Bone destruction in arthritis. Ann. Rheum. Dis., 2002, 61:ii84-ii86

[54] Chang BY et al. The Bruton tyrosine kinase inhibitor PCI-32765 ameliorates autoimmune arthritis by inhibition of multiple effector cells. Arthritis Res. Ther., 2011, 13:R115

[55] van der Heijde DM. Joint erosions and patients with early rheumatoid arthritis. Br. J. Rheumatol., 1995, 34:74-78

[56] Kuriyama K et al. A novel anti-rheumatic drug, T-614, stimulates osteoblastic differentiation in vitro and bone morphogenetic protein-2-induced bone formation in vivo. Biochem. Biophys. Res. Commun., 2002, 299:903-909

[57] Murao H et al. Iguratimod, a disease-modifying antirheumatic drug, suppressed osteoclast differentiation: P1d-13in vitro: P1d-13. Int. J. Rheum. Dis., 2008, 11:A112

[58] Gan K et al. Iguratimod (T-614) suppresses RANKL-induced osteoclast differentiation and migration in RAW264.7 cells via NF-kappaB and MAPK pathways. Int. Immunopharmacol., 2016, 35:294-300

[59] Roodman GD. Genes associate with abnormal bone cell activity in bone metastasis. Cancer Metastas-. Rev., 2012, 31:569-578

[60] Roodman GD. Mechanisms of bone metastasis. New Engl. J. Med., 2004, 350:1655-1664

[61] Sun Y et al. Anti-rheumatic drug iguratimod (T-614) alleviates cancer-induced bone destruction via down-regulating interleukin-6 production in a nuclear factor-kappaB-dependent manner. J. Huazhong Univ. Sci. Technol. Med. Sci., 2016, 36:691-699

[62] Wu YX et al. Iguratimod prevents ovariectomyinduced bone loss and suppresses osteoclastogenesis via inhibition of peroxisome proliferatoractivated receptorgamma. Mol. Med. Rep., 2017, 16:8200-8208

[63] Sun Y et al. Anti-rheumatic drug iguratimod protects against cancer-induced bone pain and bone destruction in a rat model. Oncol. Lett., 2017, 13:4849-4856

[64] Lu LJ et al. Safety and efficacy of T-614 in the treatment of patients with active rheumatoid arthritis: a double blind, randomized, placebo-controlled and multicenter trial. Chin. Med. J., 2008, 121:615-619

[65] Organization WH. Good Health Adds Life to Years: Global Brief for World Health Day 2012, 2012 Geneva World Health Organization

[66] Heiberg T et al. Seven year changes in health status and priorities for improvement of health in patients with rheumatoid arthritis. Ann. Rheum. Dis., 2005, 64:191-195

[67] Tanaka K et al. Inhibitory effects of an anti-rheumatic agent T-614 on immunoglobulin production by cultured B cells and rheumatoid synovial tissues engrafted into SCID mice. Rheumatology, 2003, 42:1365-1371

[68] Okamura K et al. Efficacy of the clinical use of iguratimod therapy in patients with rheumatoid arthritis. Mod. Rheumatol., 2015, 25:235-240

[69] Zhao L et al. SAT0037 Iguratimod ameliorates bleomycin-induced alveolar inflammation and pulmonary fibrosis in mice by suppressing expression of mmp-9. Ann. Rheum. Dis., 2018, 77:883-883

[70] Tokunaga K et al. AB0488 disease activity at one year after addition of iguratimod or sulfasalazine to methotrexate in japanese patients with rheumatoid arthritis: propensity score analysis. Ann. Rheum. Dis., 2018, 77:1404

[71] Mimori T et al. Safety and effectiveness of 24-week treatment with iguratimod, a new oral disease-modifying antirheumatic drug, for patients with rheumatoid arthritis: interim analysis of a post-marketing surveillance study of 2679 patients in Japan. Mod. Rheumatol., 2017, 27:755-765

[72] Okamura K et al. Efficacy at 52 weeks of daily clinical use of iguratimod in patients with rheumatoid arthritis. Mod. Rheumatol., 2015, 25:534-539

[73] Arita Y et al. Pneumocystis jirovecii pneumonia developed in a patient with rheumatoid arthritis after 14 weeks of iguratimod add-on to treatment with methotrexate and etanercept. Mod. Rheumatol., 2018, 28:1041-1043

[74] Kanayama Y et al. THU0212 the improvement of ultrasonographic findings for 24 weeks may predict remission at 52 weeks in japanese rheumatoid arthritis patients treated with iguratimod therapy. Ann. Rheum. Dis., 2017, 76:284

[75] Xia Z et al. Iguratimod in combination with methotrexate in active rheumatoid arthritisIguratimod in Kombination mit Methotrexat bei aktiver rheumatoider Arthritis. Z. Rheumatol., 2016, 75:828-833

[76] Duan XW et al. Efficacy and safety evaluation of a combination of iguratimod and methotrexate therapy for active rheumatoid arthritis patients: a randomized controlled trial. Clin. Rheumatol., 2015, 34:1513-1519

[77] Hara M et al. Safety and efficacy of combination therapy of iguratimod with methotrexate for patients with active rheumatoid arthritis with an inadequate response to methotrexate: an open-label extension of a randomized, double-blind, placebo-controlled trial. Mod. Rheumatol., 2014, 24:410-418

[78] Wei Y et al. Inhibitory effect of a novel antirheumatic drug T-614 on the IL-6-induced RANKL/OPG, IL-17, and MMP-3 expression in synovial fibroblasts from rheumatoid arthritis patients. Biomed. Res. Int., 2015, 2015:214683

[79] Hirano Y et al. THU0214 Long-term outcome of iguratimod, conventional synthetic disease-modifyng anti-rheumatic drud developed in japan, in japanese patients with rheumatoid arthritis in real-world clinical setting. Ann. Rheum. Dis., 2017, 76:285

[80] Yoshioka Y et al. Disease activity early in treatment as a predictor of future low disease activity in RA patients treated with iguratimod. Mod. Rheumatol., 2016, 26:169-174

[81] Xiao W et al. Genetic predictors of efficacy and toxicity of iguratimod in patients with rheumatoid arthritis. Pharmacogenomics, 2018, 19:383-392

[82] Du F et al. T-614 alters the production of matrix metalloproteinases (MMP-1 andMMP-3) and inhibits the migratory expansion of rheumatoid synovial fibroblasts, in vitro. Int. Immunopharmacol., 2012, 13:54-60

[83] Ward MM et al. American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network 2015 recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis. Arthritis Rheumatol., 2016, 68:282-298

[84] Luo Y et al. Is iguratimod effective in refractory axial spondyloarthritis? Scand. J. Rheumatol., 2018, 47:518-520

[85] Demoruelle MK et al. Connective tissue disease-related interstitial lung disease. Best. Pract. Res. Clin. Rheumatol., 2016, 30:39-52

[86] Liu TC, Stappenbeck TS. Genetics and pathogenesis of inflammatory bowel disease. Annu. Rev. Pathol., 2016, 11:127-148

[87] Khor B et al. Genetics and pathogenesis of inflammatory bowel disease. Nature, 2011, 474:307-317

[88] Jiang XP et al. Iguratimod ameliorates inflammatory responses by modulating the Th17/Treg paradigm in dextran sulphate sodium-induced murine colitis. Mol. Immunol., 2018, 93:9-19

[89] Newburger JW et al. Kawasaki disease. J. Am. Coll. Cardiol., 2016, 67:1738-1749

[90] Eleftheriou D et al. Management of Kawasaki disease. Arch. Dis. Child., 2014, 99:74-83

[91] Zhao L et al. Administration of iguratimod suppresses development of arteritis in a murine model of Kawasaki disease. Int. J. Clin. Exp. Med., 2017, 10:9180-9188

[92] Habibi S. Review of refractory lupus nephritis. Int. J. Clin. Rheumtol., 2013, 8:61

[93] Yan Q et al. 108 Iguratimod inhibits human b cell terminal differentiation in vitro and may benefit patients with refractory lupus nephritis. Lupus Sci. Med., 2017, 4:A47

[94] Yan Q et al. Prevention of immune nephritis by the small molecular weight immunomodulator iguratimod in MRL/lpr mice. PloS ONE, 2014, 9

[95] Sakamoto T et al. Inhibitory effect of anti-rheumatic drug iguratimod for hepatocellular carcinogenesis by inhibition of serum interleukin-8 production. Anticancer Res., 2016, 36:3301-3306

[96] Li XL et al. Suspected drug-induced liver injury associated with iguratimod: a case report and review of the literature. BMC Gastroenterol., 2018, 18:130

[97] Espat N et al. Tumour necrosis factor and cachexia: a current perspective. Surg. Oncol., 1994, 3:255-262

[98] Strassmann G et al. Evidence for the involvement of interleukin 6 in experimental cancer cachexia. J. Clin. Invest., 1992, 89:1681-1684

[99] Rall LC, Roubenoff R. Rheumatoid cachexia: metabolic abnormalities, mechanisms and interventions. Rheumatol. (Oxf.), 2004, 43:1219-1223

[100] Tanaka K et al. Effect of iguratimod and other anti-rheumatic drugs on adenocarcinoma colon 26-induced cachexia in mice. Inflamm. Res., 2007, 56:17-23

[101] Ooka S et al. Effects of iguratimod on protein profiles of chondrosarcoma cells. Integr. Mol. Med., 2017, 4:1-8

[102] Aikawa Y et al. A new anti-rheumatic drug, T-614, effectively suppresses the development of autoimmune encephalomyelitis. J. Neuroimmunol., 1998, 89:35-42

[103] Li G et al. Novel disease-modifying anti-rheumatic drug iguratimod suppresses chronic experimental autoimmune encephalomyelitis by down-regulating activation of macrophages/microglia through an NF-κB pathway. Sci. Rep., 2018, 8

[104] Bloom J et al. Identification of iguratimod as an inhibitor of macrophage migration inhibitory factor (MIF) with steroid-sparing potential. J. Biol. Chem., 2016, 291:26502-26514

[105] Morimoto K et al. Anti-allodynic action of the disease-modifying anti-rheumatic drug iguratimod in a rat model of neuropathic pain. Inflamm. Res., 2017, 66:855-862

[106] Lu LJ et al. Multicenter, randomized, double-blind, controlled trial of treatment of active rheumatoid arthritis with T-614 compared with methotrexate. Arthritis Rheum., 2009, 61:979-987

[107] Yamamoto T et al. Pharmacokinetic and pharmacodynamic analyses of drug-drug interactions between iguratimod and warfarin. Yakugaku Zasshi J. Pharm. Soc. Jpn., 2016, 136:905

[108] Mimori T et al. Safety and effectiveness of iguratimod in patients with rheumatoid arthritis: Final report of a 52-week, multicenter postmarketing surveillance study. Mod. Rheumatol., 2019, 29:314-323

Funding

Natural Science Foundation of Shandong Province (Shandong Provincial Natural Science Foundation)(ZR2012HM038)

Shenzhen Science and Technology Innovation Commission(JCYJ2016033117365255)

China international medical foundation(Simcere-Z-2014-06-2-1635); China torch program(2013GH021476).